Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377014581> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4377014581 endingPage "S735" @default.
- W4377014581 startingPage "S735" @default.
- W4377014581 abstract "Multiple randomized controlled trials have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) decrease the composite endpoint of cardiovascular death or heart failure hospitalizations in heart failure patients. But it is uncertain whether SGLT2i impact the risk of sudden cardiac death in these patients with heart failure. We conducted a meta-analysis of SGLT2i randomized controlled trials to determine the impact of SGLT2i therapy on arrhythmic outcomes in patients with heart failure receiving optimal medical therapy. A comprehensive search was performed to identify relevant data published prior to August 28, 2022. Randomized controlled trials were included if: 1) all patients had clinical heart failure 2) SGLT2i and placebo were compared 3) all patients received conventional medical therapy and 4) there were the reported outcomes of interest (SCD, ventricular arrhythmias, atrial arrhythmias). SCD was reported in seven of the eleven trials meeting selection criteria. Taken together, 10,796 patients received SGLT2i and 10,796 received placebo. SGLT2i therapy was associated with a significant reduction in the risk of SCD (RR 0.68; 95% CI 0.48–0.95; p = 0.03) with minimal heterogeneity between studies (I2 = 0%). Without the benefit of dedicated rhythm monitoring, there were no significant differences in the incidence of sustained ventricular arrhythmias not associated with SCD (RR 1.03; 95% CI, 0.83–1.29; p = 0.77; I2 = 0%) or atrial arrhythmias (RR 0.91; 95% CI, 0.77–1.09; p = 0.31; I2 = 29%) between patients receiving an SGLT2i vs placebo. SGLT2i therapy is associated with a reduced risk of SCD in patients with heart failure receiving contemporary medical therapy." @default.
- W4377014581 created "2023-05-19" @default.
- W4377014581 creator A5004072348 @default.
- W4377014581 creator A5009565927 @default.
- W4377014581 creator A5013824407 @default.
- W4377014581 creator A5016173778 @default.
- W4377014581 creator A5025746169 @default.
- W4377014581 creator A5031317961 @default.
- W4377014581 creator A5042772889 @default.
- W4377014581 creator A5045400007 @default.
- W4377014581 creator A5059900315 @default.
- W4377014581 creator A5063097243 @default.
- W4377014581 creator A5091734035 @default.
- W4377014581 date "2023-05-01" @default.
- W4377014581 modified "2023-09-27" @default.
- W4377014581 title "PO-455617-21 SGLT2 INHIBITORS REDUCE RISK OF SUDDEN CARDIAC DEATH IN PATIENTS WITH HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS" @default.
- W4377014581 doi "https://doi.org/10.1016/j.hrthm.2023.03.1521" @default.
- W4377014581 hasPublicationYear "2023" @default.
- W4377014581 type Work @default.
- W4377014581 citedByCount "0" @default.
- W4377014581 crossrefType "journal-article" @default.
- W4377014581 hasAuthorship W4377014581A5004072348 @default.
- W4377014581 hasAuthorship W4377014581A5009565927 @default.
- W4377014581 hasAuthorship W4377014581A5013824407 @default.
- W4377014581 hasAuthorship W4377014581A5016173778 @default.
- W4377014581 hasAuthorship W4377014581A5025746169 @default.
- W4377014581 hasAuthorship W4377014581A5031317961 @default.
- W4377014581 hasAuthorship W4377014581A5042772889 @default.
- W4377014581 hasAuthorship W4377014581A5045400007 @default.
- W4377014581 hasAuthorship W4377014581A5059900315 @default.
- W4377014581 hasAuthorship W4377014581A5063097243 @default.
- W4377014581 hasAuthorship W4377014581A5091734035 @default.
- W4377014581 hasBestOaLocation W43770145811 @default.
- W4377014581 hasConcept C126322002 @default.
- W4377014581 hasConcept C142724271 @default.
- W4377014581 hasConcept C164705383 @default.
- W4377014581 hasConcept C168563851 @default.
- W4377014581 hasConcept C203092338 @default.
- W4377014581 hasConcept C204787440 @default.
- W4377014581 hasConcept C27081682 @default.
- W4377014581 hasConcept C2775935837 @default.
- W4377014581 hasConcept C2778198053 @default.
- W4377014581 hasConcept C44249647 @default.
- W4377014581 hasConcept C71924100 @default.
- W4377014581 hasConcept C82789193 @default.
- W4377014581 hasConcept C95190672 @default.
- W4377014581 hasConceptScore W4377014581C126322002 @default.
- W4377014581 hasConceptScore W4377014581C142724271 @default.
- W4377014581 hasConceptScore W4377014581C164705383 @default.
- W4377014581 hasConceptScore W4377014581C168563851 @default.
- W4377014581 hasConceptScore W4377014581C203092338 @default.
- W4377014581 hasConceptScore W4377014581C204787440 @default.
- W4377014581 hasConceptScore W4377014581C27081682 @default.
- W4377014581 hasConceptScore W4377014581C2775935837 @default.
- W4377014581 hasConceptScore W4377014581C2778198053 @default.
- W4377014581 hasConceptScore W4377014581C44249647 @default.
- W4377014581 hasConceptScore W4377014581C71924100 @default.
- W4377014581 hasConceptScore W4377014581C82789193 @default.
- W4377014581 hasConceptScore W4377014581C95190672 @default.
- W4377014581 hasIssue "5" @default.
- W4377014581 hasLocation W43770145811 @default.
- W4377014581 hasOpenAccess W4377014581 @default.
- W4377014581 hasPrimaryLocation W43770145811 @default.
- W4377014581 hasRelatedWork W1885119863 @default.
- W4377014581 hasRelatedWork W2073750123 @default.
- W4377014581 hasRelatedWork W2114346778 @default.
- W4377014581 hasRelatedWork W2230641066 @default.
- W4377014581 hasRelatedWork W2335438131 @default.
- W4377014581 hasRelatedWork W2531052508 @default.
- W4377014581 hasRelatedWork W2592774827 @default.
- W4377014581 hasRelatedWork W2626084264 @default.
- W4377014581 hasRelatedWork W2903890959 @default.
- W4377014581 hasRelatedWork W4212933565 @default.
- W4377014581 hasVolume "20" @default.
- W4377014581 isParatext "false" @default.
- W4377014581 isRetracted "false" @default.
- W4377014581 workType "article" @default.